CN108472255A - 调节胞质dna监测分子的方法 - Google Patents

调节胞质dna监测分子的方法 Download PDF

Info

Publication number
CN108472255A
CN108472255A CN201680049705.XA CN201680049705A CN108472255A CN 108472255 A CN108472255 A CN 108472255A CN 201680049705 A CN201680049705 A CN 201680049705A CN 108472255 A CN108472255 A CN 108472255A
Authority
CN
China
Prior art keywords
seq
nucleic acid
sequence
immune
modulator composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680049705.XA
Other languages
English (en)
Chinese (zh)
Inventor
T.伊尔格
A.阿伯拉罕
J.尼克尔
D.凯尔
C.魏斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco Animal Health GmbH
Original Assignee
Bayer Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health GmbH filed Critical Bayer Animal Health GmbH
Publication of CN108472255A publication Critical patent/CN108472255A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201680049705.XA 2015-06-26 2016-06-23 调节胞质dna监测分子的方法 Pending CN108472255A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26
US62/185230 2015-06-26
PCT/EP2016/064613 WO2016207314A2 (en) 2015-06-26 2016-06-23 Methods of modulating cytosolic dna surveillance molecules

Publications (1)

Publication Number Publication Date
CN108472255A true CN108472255A (zh) 2018-08-31

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680049705.XA Pending CN108472255A (zh) 2015-06-26 2016-06-23 调节胞质dna监测分子的方法

Country Status (22)

Country Link
US (1) US20190233825A1 (https=)
EP (1) EP3313376A2 (https=)
JP (1) JP2018518511A (https=)
KR (1) KR20180021874A (https=)
CN (1) CN108472255A (https=)
AR (1) AR105160A1 (https=)
AU (1) AU2016282879A1 (https=)
BR (1) BR112017028121A2 (https=)
CA (1) CA2990526A1 (https=)
CL (1) CL2017003373A1 (https=)
CR (1) CR20180003A (https=)
DO (1) DOP2017000313A (https=)
HK (1) HK1256128A1 (https=)
IL (1) IL256264A (https=)
MX (1) MX2017017141A (https=)
PE (1) PE20181208A1 (https=)
PH (1) PH12017502413A1 (https=)
RU (1) RU2018102915A (https=)
SG (1) SG10201913395VA (https=)
TW (1) TW201710509A (https=)
UY (1) UY36756A (https=)
WO (1) WO2016207314A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170078843A (ko) 2014-11-21 2017-07-07 노오쓰웨스턴 유니버시티 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
CN109689095B (zh) 2016-07-26 2023-10-03 拜耳动物保健有限责任公司 牛物种中增加的生育力
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066879A2 (en) * 1998-06-25 1999-12-29 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
EP1326969A2 (en) * 2000-09-25 2003-07-16 Valentis Inc. Improved system for regulation of transgene expression
CN103501810A (zh) * 2010-12-22 2014-01-08 拜耳知识产权有限责任公司 牛物种中增强的免疫应答

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
TW200505425A (en) * 2003-05-29 2005-02-16 Schering Plough Ltd Compositions and method for treating infection in cattle and swine
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失ｄｎａワクチン
US8906664B2 (en) * 2004-08-13 2014-12-09 The Trustees Of The University Of Pennsylvania Methods for constructing antibiotic resistance free vaccines
BRPI1010803A2 (pt) * 2009-05-14 2018-06-12 Bayer Animal Health Gmbh "resposta imune aumentada na espécie aviária"
US9359602B2 (en) * 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
EP3110940A1 (en) * 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunostimulatory plasmids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1999066879A2 (en) * 1998-06-25 1999-12-29 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1326969A2 (en) * 2000-09-25 2003-07-16 Valentis Inc. Improved system for regulation of transgene expression
CN103501810A (zh) * 2010-12-22 2014-01-08 拜耳知识产权有限责任公司 牛物种中增强的免疫应答

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GHANIA CHIKH等: ""Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles"", 《INTERNATIONAL IMMUNOLOGY,》 *
KOUJI KOBIYAMA等: ""Innate ImmuneGenetic Adjuvants for DNA VACCINES"", 《VACCINES》 *
M .RERAT等: ""Bovine respiratorydisease:Efficacy of different prophylactic treatments in veal calves and antimicrobial resistance of isolated Pasteurellaceae"", 《PREUENTIUE VETERINARY MEDICINE》 *
MARIJKE KEESTRA等: ""Chicken TLR21is an innate CpG DNA receptor distinctfrom mammalian TLR9"", 《THE JOURNAL OF IMMUNOLOGY》 *

Also Published As

Publication number Publication date
CR20180003A (es) 2018-03-20
IL256264A (en) 2018-02-28
JP2018518511A (ja) 2018-07-12
WO2016207314A3 (en) 2017-02-09
BR112017028121A2 (pt) 2018-09-04
WO2016207314A2 (en) 2016-12-29
CL2017003373A1 (es) 2018-06-29
MX2017017141A (es) 2018-03-09
RU2018102915A3 (https=) 2019-12-05
SG10201913395VA (en) 2020-03-30
KR20180021874A (ko) 2018-03-05
EP3313376A2 (en) 2018-05-02
UY36756A (es) 2017-01-31
CA2990526A1 (en) 2016-12-29
TW201710509A (zh) 2017-03-16
DOP2017000313A (es) 2018-02-28
HK1256128A1 (zh) 2019-09-13
AR105160A1 (es) 2017-09-13
PE20181208A1 (es) 2018-07-23
RU2018102915A (ru) 2019-07-29
AU2016282879A1 (en) 2018-01-18
PH12017502413A1 (en) 2018-06-25
US20190233825A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
US10851379B2 (en) Immunostimulatory plasmids
RU2606855C2 (ru) Повышение иммунного отклика у видов крупного рогатого скота
CN108472255A (zh) 调节胞质dna监测分子的方法
US20180326049A1 (en) Enhanced immune response in porcine species
TWI759317B (zh) 牛物種中增加的生育力
TWI733688B (zh) 水生物種中增強之免疫反應
BR112018002107B1 (pt) Uso de um imunomodulador para potencializar resposta imune em espécies suínas
HK1190628A (en) Enhanced immune response in bovine species

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256128

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180831

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1256128

Country of ref document: HK